BIIBBiogen
Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases. 10-K, Item 1
- Employees
- 7,500
- Headquarters
- Cambridge, MA
- Next results
- around Jan 13, 2027
The numbers BIIB said it expected, in its earnings releases of the last 3 years, next to what it then reported for the same period. Each target links to the sentence in the release; each result to the 10-Q or 10-K it was first reported in.
| Target | What the company said | Reported | Result |
|---|---|---|---|
| Diluted EPS (company-defined) Fiscal 2026 |
Given $15.25 to $16.25 release 2026-02-06
Lowered $14.25 to $15.25 release 2026-04-29
|
– | No standard number |
The company's wordsFull year 2026 Non-GAAP diluted EPS expected to be between $15.25 and $16.25 release 2026-02-06 Full year 2026 Non-GAAP diluted EPS is now expected to be between $14.25 and $15.25, excluding any impact from the Apellis transaction. release 2026-04-29 | |||
| Diluted EPS (company-defined) Fiscal 2025 (ended 2025-12-31) |
Given $15.25 to $16.25 release 2025-02-12
Narrowed $15.50 to $16.00 release 2025-07-31
Lowered $14.50 to $15.00 release 2025-10-30
|
– | No standard number |
The company's wordsFull year 2025 financial guidance: Non-GAAP diluted EPS expected between $15.25 and $16.25 release 2025-02-12 Increased expected full year 2025 Non-GAAP diluted EPS to between $15.50 and $16.00, up from between $14.50 and $15.50 previously release 2025-07-31 Full year 2025 Non-GAAP diluted EPS expected to be between $14.50 and $15.00, including expected improved business impact of approximately $0.25 EPS, offset by an expected approximately ($1.25) EPS impact in the fourth quarter from acquired IPR&D expense release 2025-10-30 | |||
| Diluted EPS (company-defined) Fiscal 2024 (ended 2024-12-31) |
Given $15.00 to $16.00 release 2024-02-13
Kept $15.00 to $16.00 release 2024-04-24
Raised $15.75 to $16.25 release 2024-08-01
Raised $16.10 to $16.60 release 2024-10-30
|
– | No standard number |
The company's wordsFull year 2024 financial guidance: Non-GAAP EPS of $15.00 to $16.00, representing EPS growth of approximately 5% versus 2023 at the mid-point release 2024-02-13 Reaffirming full year 2024 financial guidance: Non-GAAP EPS of $15.00 to $16.00, representing EPS growth of approximately 5% versus 2023 at the mid-point release 2024-04-24 Increasing full year 2024 financial guidance: Non-GAAP EPS now expected to be between $15.75 and $16.25, representing EPS growth of approximately 9% at the mid-point versus full year 2023 release 2024-08-01 Increasing full year 2024 financial guidance: Non-GAAP diluted EPS now expected to be between $16.10 and $16.60, representing Non-GAAP diluted EPS growth of approximately 11% at the mid-point versus full year 2023 release 2024-10-30 | |||
Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (13 releases since 2023-11-08), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.
Work on BIIB in a spreadsheet:
Excel workbook (a sheet per section, ten years by column, charts, links to the filings) ·
CSV.
For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/BIIB/export.csv") into a cell.